#USA #CordenPharma #North Augusta #AmbioPharm #Peptide API

CordenPharma's Strategic Acquisition of AmbioPharm

In a significant strategic move, CordenPharma, a global leader in contract development and manufacturing (CDMO), has announced the acquisition of AmbioPharm, a respected player in peptide API manufacturing. This acquisition, aimed at enhancing CordenPharma's global capacity for peptide products, will integrate AmbioPharm's facilities located in North Augusta, South Carolina, and Shanghai, China.

Expanding Production Capabilities

The acquisition emphasizes strengthening CordenPharma’s peptide production capabilities in the United States, while also offering an expanded global expertise in handling complex peptide APIs. By integrating AmbioPharm’s resources, CordenPharma aims to offer its clients an even broader selection of manufacturing options, scaling pathways, and regional/global supply models.

AmbioPharm, which employs approximately 400 staff across its location, brings to the table a wealth of experience in producing high-purity peptides. This acquisition will not only augment CordenPharma's existing capabilities in peptide synthesis but also add to their end-to-end support for peptide drug development and commercialization needs. AmbioPharm’s cutting-edge technologies, such as solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), perfectly align with CordenPharma's existing processes.

Enhancing Global Reach

Integrating AmbioPharm further reinforces CordenPharma's established network of 11 operating sites across Europe and North America. This strategic addition will provide a significant boost in production capacity for peptide APIs, thereby directly addressing the rising demand for peptides in pharmaceuticals. The North Augusta, SC site will focus extensively on purification and lyophilization processes for API peptides following the acquisition.

CordenPharma's existing facilities in Colorado will also be enhanced through this merger, aligning production capabilities entirely within the U.S. to cater to substantial peptide projects. Meanwhile, the Shanghai facility will enable CordenPharma to tap into advanced capabilities in producing global clinical and commercial peptide supplies.

A New Chapter in Peptide Development

The CEO of CordenPharma, Dr. Michael Quirmbach, stated that this acquisition significantly bolsters the Peptides platform at CordenPharma, paving the way toward becoming a leading partner in peptide production. He highlighted the growing complexity of peptide-based programs that require a partner that can provide not only scientific expertise but also robust process capabilities and integrated geographic flexibility.

AmbioPharm’s CEO, Brian Gregg, conveyed excitement over the merger, stating that it signifies an important new chapter for both companies. The integration will result in broader technical capabilities and enhanced global capacity, enabling a reliable Peptides platform that supports efficient development and commercialization of peptide-based drugs worldwide.

Long-term Growth and Market Potential

Since the acquisition of CordenPharma by Astorg in 2022, the organization has been on a strategic expansion trajectory to bolster its peptide platform through targeted investments. This acquisition represents strong confidence from AmbioPharm’s shareholders, who will reinvest in the combined business, indicating their commitment to enhancing capabilities and realizing the growth potential of the expanded Peptides platform.

With the global peptide market on the rise, CordenPharma’s latest development steps showcase its ongoing commitment to preparing for the future, keeping the needs of patients at the forefront. Significant growth opportunities lie ahead as they seek to enhance their market positioning in the ever-evolving space of peptide therapeutics.

In conclusion, the acquisition of AmbioPharm positions CordenPharma as a major player in the expanding peptide contract manufacturing market while setting a pathway for sustained growth and improved patient outcomes globally.